Insomnia: Definition, Prevalence, Etiology, and Consequences

Free AccessSupplementInsomnia: Definition, Prevalence, Etiology, and Consequences Thomas Roth, PhD Thomas Roth, PhD Address correspondence to: Thomas Roth, PhD, Director of Research, Sleep Disorders and Research Center at Henry Ford Health System, Henry Ford Hospital Sleep Center, 2799 West Grand Blvd., Detroit, MI 48202(313) 876-2233(313) 916-5150 E-mail Address: [email protected] Sleep Disorders and Research Center, Henry Ford Hospital Detroit, MI Search for more papers by this author Published Online:November 14, 2019https://doi.org/10.5664/jcsm.26929Cited by:414SectionsPDF ShareShare onFacebookTwitterLinkedInRedditEmail ToolsAdd to favoritesDownload CitationsTrack Citations AboutDEFINITION OF INSOMNIA The term insomnia is used in a variety of ways in the medical literature and popular press. Most often, insomnia is defined by the presence of an individual's report of difficulty with sleep. For example, in survey studies, insomnia is defined by a positive response to either question, “Do you experience difficulty sleeping?” or “Do you have difficulty falling or staying asleep?” In the sleep literature, insomnia is sometimes used as a term to describe the presence of polysomnographic evidence of disturbed sleep. Thus, the presence of a long sleep latency, frequent nocturnal awakenings, or prolonged periods of wakefulness during the sleep period or even frequent transient arousals are taken as evidence of insomnia.1 Thus, insomnia has been thought of both as a symptom and as a sign. However, for the purpose of this paper, the term insomnia will be used as a disorder with the following diagnostic criteria: (1) difficulty falling asleep, staying asleep or nonrestorative sleep; (2) this difficulty is present despite adequate opportunity and circumstance to sleep; (3) this impairment in sleep is associated with daytime impairment or distress; and (4) this sleep difficulty occurs at least 3 times per week and has been a problem for at least 1 month. What qualifies insomnia to be considered a disorder? A disorder is a condition associated with negative consequences, and importantly, these consequences are not a normal result of the condition but rather the result of some sort of pathological response. In the present discussion, the consequences of insomnia can not merely be the normal consequence of sleep loss.PREVALENCE OF INSOMNIA Estimates of the prevalence of insomnia depend on the criteria used to define insomnia and more importantly the population studied. A general consensus has developed from population-based studies that approximately 30% of a variety of adult samples drawn from different countries report one or more of the symptoms of insomnia: difficulty initiating sleep, difficulty maintaining sleep, waking up too early, and in some cases, nonrestorative or poor quality of sleep.2 Conclusions from the NIH State-of-the-Science Conference held in June 2005 indicate that the addition of a diagnostic requirement that includes perceived daytime impairment or distress as a function of the insomnia symptoms results in approximately 10% prevalence of insomnia.3 Finally, the application of more stringent diagnostic criteria, such as the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV),4 which includes the additional requirements that insomnia symptoms persist for at least 1 month and do not exclusively occur in the presence of another sleep disorder, mental disorder, or the direct physiological effects of a substance or medical condition, yields current prevalence estimates of approximately 6%.5 Several well-identified risk factors for insomnia were reported by the State-of-the-Science Conference in June 2005.3 Age and gender are the most clearly identified demographic risk factors, with an increased prevalence in women and older adults. While the cause of this increased risk in the elderly is not well defined, it may be due to the partial decline in functionality of sleep control systems that may contribute to insomnia in this older population. Importantly, the presence of comorbid medical conditions is also a significant contributor to the increased prevalence of insomnia in the elderly. Additionally, in women, insomnia is more prevalent with both the onset of menses and menopause.6 Comorbid medical disorders,7 psychiatric disorders,8 and working night or rotating shifts9 all represent significant risks for insomnia. It is important to recognize that these factors do not independently cause insomnia, but rather they are precipitants of insomnia in individuals predisposed to this disorder. In fact, chronic illnesses are a significant risk for insomnia. It is estimated that the majority of people with insomnia (approximately 75%–90%) have an increased risk for comorbid medical disorders,7 such as conditions causing hypoxemia and dyspnea, gastroesophageal reflux disease, pain conditions, and neurodegenerative diseases. Importantly, a variety of primary sleep disorders as well as circadian rhythm disorders are frequently comorbid with and often lead to insomnia. Among the primary sleep disorders, restless legs syndrome (RLS),10 periodic limb movement disorders (PLMD), and sleep-related breathing disorders (snoring, dyspnea, sleep apnea) often present with an insomnia symptom.11 This is especially true among the elderly. Among younger individuals, difficulty falling asleep is often associated with a phase delay syndrome. However, in the elderly, phase advance syndrome results in reports of difficulty initiating sleep, maintaining sleep, and experiencing early morning awakenings.12–14 The most common comorbidities associated with insomnia are psychiatric disorders. It is estimated that 40% of all insomnia patients have a coexisting psychiatric condition.8,15 Among these psychiatric disorders, depression is the most common, and insomnia is a diagnostic symptom for depressive and anxiety disorders.11CONSEQUENCES OF INSOMNIA Due to its chronicity, insomnia is associated with substantial impairments in an individual's quality of life. In several studies, insomniacs reported decreased quality of life on virtually all dimensions of the 36-item Short Form Health Survey of the Medical Outcomes Study (SF-36), which assesses 8 domains: (1) physical functioning; (2) role limitation due to physical health problems (role physical); (3) bodily pain; (4) general health perceptions; (5) vitality; (6) social functioning; (7) role limitations due to emotional health problems (role emotional); and (8) mental health.16–18 One study compared SF-36 results in groups of mild and severe insomnia patients with groups of patients diagnosed with depression or congestive heart failure (CHF).19 Severe insomnia patients had numerically greater loss of function than patients with CHF in reported pain, emotional effects, and mental health effects. Additionally, insomnia patients also reported more physical problems than patients with depression.19 Research has shown that among the daytime consequences of insomnia, the increased occurrence of accidents poses the greatest health risk. Insomniacs are 2.5 to 4.5 times more likely than controls to have an accident.20,21 In a sample of 8,625 community respondents in France, Léger et al. reported that 8% of insomniacs and 1% of non-insomniacs had an industrial accident in the past 12 months.22 Work productivity is also compromised among insomniacs due to work-related problems (ie, higher rates of absenteeism, decreased concentration, and difficulty performing duties). Kuppermann and colleagues23 found that individuals reporting a current sleep problem were more likely than good sleepers to have decreased job performance and to have been absent from work in the last month due to health problems. Simon and VonKorff24 evaluated insomnia in a staff-model health maintenance organization population (N=1,962). After adjusting for age, gender, and chronic disease, days of restricted activity due to illness and days spent in bed were about twice as common among insomniacs compared with non-insomniacs. Additionally, mean total health care expenditures were 60% higher in the insomnia group relative to the controls. Population- and clinic-based studies have demonstrated a high rate of psychiatric comorbidities in patients with chronic insomnia. In fact, insomnia is more frequently associated with psychiatric disorders than any other medical illness.25 For example, in the Epidemiologic Catchment Area study, 40% of insomniacs had a comorbid psychiatric disorder compared with 16.4% of those with no sleep complaints.8 Additionally, depression and anxiety are the most common comorbid psychiatric disorders in insomniacs. It has traditionally been assumed that insomnia is secondary to the psychiatric disorder; however, given the chronicity of insomnia, it is possible that in some, if not most, cases the insomnia precedes the psychiatric disorder. In fact, it is possible that insomnia represents a significant risk for the development of a subsequent psychiatric disorder. In a large-scale European population-based study (N=14,915), it was found that insomnia more often preceded rather than followed incident cases of a mood disorder.26 This effect is even more pronounced for relapses of the mood disorder, where in 56.2% of cases, insomnia symptoms preceded symptoms of a mood disorder relapse. In contrast, in chronic insomnia patients with a comorbid anxiety disorder, the first occurrence of anxiety or a relapse preceded insomnia in most instances. To further understand the relation of sleep and psychiatric disorders, several longitudinal studies have examined the evolution of psychiatric disorders among insomnia patients. These studies used follow-up periods ranging from 1 to 40 years, with the majority using a 1- to 3-year follow-up period. In all of these studies, insomnia has been found to confer a substantial risk for the development of a depressive disorder.27,28 Typically, the relative risk was approximately 5 (range 2–40), and in all cases it was statistically significant. While some studies also reported an increased risk for anxiety or drug abuse, neither of these was consistently found. Finally, longitudinal studies in subjects with affective disorders show that depressed patients who experience improvements in sleep will also experience a more rapid antidepressant response; while those patients whose insomnia persists will have a short time to relapse.29,30 What is clearly needed are clinical trials to assess the impact of insomnia therapy on incidence of depression as well as the time to relapse in depressed patients who are in remission. The question then arises as to whether insomnia causes depression, vice versa, or both. The close association of insomnia with depression is likely related to common underlying pathophysiological mechanisms for sleep and mood regulation that make the individual vulnerable to both conditions. Data have shown that both the diagnosis of insomnia and the severity of the sleep disturbance are related to overactivation of the hypothalamic-pituitary-adrenal (HPA) axis and the hypersecretion of cortisol.31 Recent evidence suggests that there may be some neuroendocrine and clinical similarities between insomnia and depression. Corticotropin-releasing factor (CRF) dysregulation has been implicated in the pathogenesis of psychiatric disorders such as depression32 as well as in the mediation of hyperarousal seen in primary insomnia.33 This abnormality might represent the common risk factor, and therefore, it is quite possible that both disorders would respond to the same therapeutic intervention (eg, corticotropinreleasing hormone antagonists). PATHOPHYSIOLOGY OF INSOMNIA Insomnia is thought to be a disorder of hyperarousal experienced throughout the entire day. This hyperarousal may exhibit itself as a state of hypervigilance during the day and difficulty initiating and maintaining sleep at night.34,35 This arousal is currently explained by both cognitive and physiological models of insomnia. The cognitive model suggests that worry and rumination about life stresses disrupt sleep, creating acute episodes of insomnia, especially in initiating sleep and returning back to sleep after an awakening.36 Then, once an individual begins to experience sleep difficulties, worry and rumination shift from life events to worries about sleep itself and about the daytime consequences of not getting enough sleep. This negatively-toned cognitive activity is further fueled if a sleep-related threat is detected or a sleep deficit is perceived. In parallel with the cognitive models, another model of the evolution of insomnia proposes that hyperarousal is primarily due to physiologic or neurophysiologic factors. Physiological arousal has been evaluated through measurements of the whole body metabolic rate, heart rate variability, neuroendocrine measures, and functional neuroimaging. Whole body metabolic rate may be measured by oxygen consumption (VO2). Recent studies compared good sleepers with patients diagnosed with insomnia. The insomnia patients exhibited significantly higher metabolic rates (measured at intervals across the 24-hour day) than the healthy controls. Heart rate variability may provide a measure of arousal in that it is regulated by both sympathetic and parasympathetic nervous system activities. A 36-hour study37 found that average heart rates were increased and variability was decreased in all stages of sleep in insomnia patients compared to healthy normal sleepers. The neuroendocrine system may also provide evidence of arousal as demonstrated by chronic activation of the stress response system. Several studies measuring 24-hour urinary free cortisol excretion have found high levels in poor sleepers.38,39 Urinary free cortisol levels have also been positively correlated with total wake time, and urinary catecholamines have been correlated with stage 1 sleep percentage and wake time after sleep onset.38,40 Plasma measures of cortisol and adrenocorricotropic hormone (ACTH) have been evaluated in insomnia patients and healthy normal sleepers. Although the evidence is somewhat mixed, primary insomniacs appear to have higher levels of these compounds in their plasma, with the most significant differences seen in the evening and the first half of the night.38,39,41 Both the urinary and plasma measures of cortisol and ACTH suggest that the HPA axis is associated with the pathology of chronic insomnia. Finally, positron emission tomography (PET) has been used to assess cerebral glucose metabolism, an indirect measure of whole brain metabolism, in patients with insomnia.42 Compared to healthy subjects, patients with insomnia exhibited greater cerebral glucose metabolism during waking and non-rapid eye movement (REM) sleep states. Furthermore, the insomnia patients demonstrated smaller reductions in relative metabolism from waking to non-REM sleep in wake-promoting regions of the brain. These findings suggest interacting neural networks involved in the inability to fall asleep, which include a general arousal system, an emotion-regulating system, and a cognitive system. CONCLUSIONChronic insomnia is highly prevalent and affects approximately 30% of the general population. Insomnia impairs cognitive and physical functioning and is associated with a wide range of impaired daytime functions across a number of emotional, social, and physical domains. Compared with good sleepers, people with persistent sleep disturbances are more prone to accidents, have higher rates of work absenteeism, diminished job performance, decreased quality of life, and increased health care utilization. Various risk factors associated with increased prevalence of chronic insomnia include older age, female gender, and comorbid medical and psychiatric conditions. Approximately 40% of adults with insomnia also have a diagnosable psychiatric disorder—most notably depression. A comorbid psychiatric disorder such as depression or anxiety may be a consequence of—as well as a risk factor for—disrupted sleep. Recent research suggests that insomnia and depression share common pathological processes that make individuals vulnerable to both conditions—specifically, abnormal regulation of CRF. CRF regulation has been extensively implicated in the pathogenesis of depression, and hyperactivity of the HPA axis and CRF neurons could account for the hyperarousal and sleep disturbances associated with chronic insomnia. Studies that improve the knowledge of the neurobiological mechanisms controlling regulation of sleep homeostasis, circadian rhythms, physiological hyperarousal, genetics, stress, and cognition are needed to adequately evaluate the causes and mechanisms of insomnia. Effective pharmacologic and behavioral interventions to treat insomnia rely on accurate neurobehavioral and neurobiological information.Disclosure StatementDr. Roth has received research support from Aventis, Cephalon, GlaxoSmithKline, Neurocrine, Pfizer, Sanofi, SchoeringPlough, Sepracor, Somaxon, Syrex, Takeda, TransOral, Wyeth, and Xenoport; is a consultant for Abbott, Accadia, Acoglix, Actelion, Alchemers, Alza, Ancil, Arena, AstraZeneca, Aventis, BMS, Cephalon, Cypress, Dove, Elan, Eli Lilly, Evotec, Forest, GlaxoSmithKline, Hypnion, Jazz, Johnson & Johnson, King, Ludbeck, McNeil, MedicNova, Merck, Neurim, Neurocrine, Neurogen, Novartis, Orexo, Organon, Orginer, Prestwick, Proctor and Gamble, Pfizer, Purdue, Restiva, Roche, Sanofi, ShoeringPlough, Sepracor, Servier, Shire, Somaxon, Syrex, Takeda, TransOral, Vanda, Vivometrics, Wyeth, Yamanuchi, and Xenoport; and has participated in speaking engagements supported by Sanofi and Takeda.REFERENCES1 Sateia MJ , Doghramji K , Hauri PJ , Morin CMEvaluation of chronic insomnia. An American Academy of Sleep Medicine reviewSleep200023243308, 10737342 CrossrefGoogle Scholar2 Ancoli-Israel S , Roth TCharacteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I.Sleep199922Suppl 2S34753, 10394606 Google Scholar3 Sleep200528National Institutes of Health State of the Science Conference Statement on Manifestations and Management of Chronic Insomnia in AdultsJune 13–15, 2005104957, 16268373 Google Scholar4 American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders19944th Ed.Washington, D.C.APA5517Text Revision. DSM-IV-TR Google Scholar5 Ohayon MMPrevalence of DSM-IV diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disordersJ Psychiatr Res19973133346, 9306291 CrossrefGoogle Scholar6 Johnson EO , Roth T , Schultz L , Breslau NEpidemiology of DSMIV insomnia in adolescence: lifetime prevalence, chronicity, and an emergent gender differencePediatrics2006117e24756, 16452333 CrossrefGoogle Scholar7 Katz DA , McHorney CAClinical correlates of insomnia in patients with chronic illnessArch Intern Med19981581099107, 9605781 CrossrefGoogle Scholar8 Ford DE , Kamerow DBEpidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?JAMA1989262147984, 2769898 CrossrefGoogle Scholar9 Roth T , Roehrs TInsomnia: epidemiology, characteristics, and consequencesClin Cornerstone20035515, 14626537 CrossrefGoogle Scholar10 Phillips B , Hening W , Britz P , Mannino DPrevalence and correlates of restless legs syndrome: results from the 2005 National Sleep Foundation PollChest20061297680, 16424415 CrossrefGoogle Scholar11 Ancoli-Israel SThe impact and prevalence of chronic insomnia and other sleep disturbances associated with chronic illnessAm J Managed Care200612S2219 Google Scholar12 Avidan AYSleep changes and disorders in the elderly patientCurr Neurol Neurosci Rep2002217885, 11898485 CrossrefGoogle Scholar13 Avidan AYSleep in the geriatric patient populationSemin Neurol2005255263, 15798937 CrossrefGoogle Scholar14 Dement W , Richardson G , Prinz P , Carskadon M , Kripke O , Czeisler C , Finch C , Schneider ELChanges of sleep and wakefulness with ageHandbook of the Biology of Aging19962nd ed.New YorkVanNostrand Reinhold Google Scholar15 McCall WVA psychiatric perspective on insomniaJ Clin Psychiatry200162Suppl 102732, 11388587 Google Scholar16 McHorney CA , Ware JE , Raczek AEThe MOS 36-Item ShortForm Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructsMed Care19933124763, 8450681 CrossrefGoogle Scholar17 McHorney CA , Ware JE , Rogers W , Raczek AE , Lu JFThe validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes StudyMed Care199230MS25365, 1583937 CrossrefGoogle Scholar18 McHorney CA , Ware JE , Lu JF , Sherbourne CDThe MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groupsMed Care1994324066, 8277801 CrossrefGoogle Scholar19 Katz DA , McHorney CAThe relationship between insomnia and health-related quality of life in patients with chronic illnessJ Fam Pract20025122935, 11978233 Google Scholar20 Balter MB , Uhlenhuth EHNew epidemiologic findings about insomnia and its treatmentJ Clin Psychiatry199253Suppl349, 1487478 Google Scholar21 National Sleep FoundationSleep in America: A survey of US adults. A report prepared by the Gallup Organization for the National Sleep Foundation1991Los Angeles, CANational Sleep Foundation Google Scholar22 Leger D , Guilleminault C , Bader G , Levy E , Paillard MMedical and socio-professional impact of insomniaSleep2002256259, 12224841 CrossrefGoogle Scholar23 Kuppermann M , Lubeck DP , Mazonson PD , Patrick DL , Stewart AL , Buesching DP , Fifer SKSleep problems and their correlates in a working populationJ Gen Intern Med1995102532, 7699483 CrossrefGoogle Scholar24 Simon GE , VonKorff MPrevalence, burden, and treatment of insomnia in primary careAm J Psychiatry1997154141723, 9326825 CrossrefGoogle Scholar25 Benca RMConsequences of insomnia and its therapiesJ Clin Psychiatry200162Suppl 10338, 11388589 Google Scholar26 Ohayon MM , Roth TPlace of chronic insomnia in the course of depressive and anxiety disordersJ Psychiatr Res200337915, 12482465 CrossrefGoogle Scholar27 Breslau N , Roth T , Rosenthal L , Andreski PSleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adultsBiol Psychiatry19963941118, 8679786 CrossrefGoogle Scholar28 Chang PP , Ford DE , Mead LA , Cooper-Patrick L , Klag MJInsomnia in young men and subsequent depression. The Johns Hopkins Precursors StudyAm J Epidemiol199714610514, 9230772 CrossrefGoogle Scholar29 Perlis ML , Giles DE , Buysse DJ , Tu X , Kupfer DJSelf-reported sleep disturbance as a prodromal symptom in recurrent depressionJ Affect Disord19974220912, 9105962 CrossrefGoogle Scholar30 Fava GA , Grandi S , Canestrari R , Molnar GProdromal symptoms in primary major depressive disorderJ Affect Disord19901914952, 2142701 CrossrefGoogle Scholar31 Richardson GS , Roth TFuture directions in the management of insomniaJ Clin Psychiatry200162Suppl 103945, 11388590 Google Scholar32 Gold PW , Chrousos GPOrganization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE statesMol Psychiatry2002725475, 11920153 CrossrefGoogle Scholar33 Roth T , Roehrs T , Pies RInsomnia: pathophysiology and implications for treatmentSleep Med Rev200711719, 17175184 CrossrefGoogle Scholar34 Bonnet MH , Arand DL24-Hour metabolic rate in insomniacs and matched normal sleepersSleep1995185818, 8552929 CrossrefGoogle Scholar35 Stepanski E , Zorick F , Roehrs T , Young D , Roth TDaytime alertness in patients with chronic insomnia compared with asymptomatic control subjectsSleep1988115460, 3363270 CrossrefGoogle Scholar36 Harvey AGA cognitive model of insomniaBehav Res Ther20024086993, 12186352 CrossrefGoogle Scholar37 Bonnet MH , Arand DLHeart rate variability in insomniacs and matched normal sleepersPsychosom Med1998606105, 9773766 CrossrefGoogle Scholar38 Vgontzas AN , Bixler EO , Lin HM , Prolo P , Mastorakos G , Vela-Bueno A , Kales A , Chrousos GPChronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implicationsJ Clin Endocrinol Metab200186378794, 11502812 CrossrefGoogle Scholar39 Vgontzas AN , Tsigos C , Bixler EO , Stratakis CA , Zachman K , Kales A , Vela-Bueno A , Chrousos GPChronic insomnia and activity of the stress system: a preliminary studyJ Psychosom Res1998452131, 9720852 CrossrefGoogle Scholar40 Vgontzas AN , Bixler EO , Papanicolaou DA , Kales A , Stratakis CA , Vela-Bueno A , Gold PW , Chrousos GPRapid eye movement sleep correlates with the overall activities of the hypothalamic-pituitary-adrenal axis and sympathetic system in healthy humansJ Clin Endocrinol Metab199782327880, 9329353 CrossrefGoogle Scholar41 Riemann D , Klein T , Rodenbeck A , Feige B , Horny A , Hummel R , Weske G , Al-Shajlawi A , Voderholzer UNocturnal cortisol and melatonin secretion in primary insomniaPsychiatry Res20021131727, 12467942 CrossrefGoogle Scholar42 Nofzinger EA , Buysse DJ , Germain A , Price JC , Miewald JM , Kupfer DJFunctional neuroimaging evidence for hyperarousal in insomniaAm J Psychiatry200416121268, 15514418 CrossrefGoogle Scholar Previous article Next article FiguresReferencesRelatedDetailsCited by Understanding neuron-glia crosstalk and biological clocks in insomniaCarvalhas-Almeida C, Serra J, Moita J, Cavadas C and Álvaro A Neuroscience & Biobehavioral Reviews, 10.1016/j.neubiorev.2023.105100, Vol. 147, , (105100), Online publication date: 1-Apr-2023. Mental and physical health pathways linking insomnia symptoms to cognitive performance 14 years laterZaheed A, Chervin R, Spira A and Zahodne L Sleep, 10.1093/sleep/zsac262, Vol. 46, No. 3, Online publication date: 9-Mar-2023. Sleep quality and associated factors among adult people living with HIV on follow-up at Dessie Town Governmental Health Facilities Antiretroviral Therapy Clinics, Northeast, Ethiopia, 2020, a multicenter cross-sectional studyGebreEyesus F, Degu F, Yohanes Y and Azagew A BMC Psychiatry, 10.1186/s12888-023-04619-w, Vol. 23, No. 1 The prevalence of self-reported insomnia symptoms and association with metabolic outcomes in people with type 2 diabetes: the Hoorn Diabetes Care System cohortGroeneveld L, den Braver N, Beulens J, van der Heijden A, van der Reep A, Remmelzwaal S, Elders P and Rutters F Journal of Clinical Sleep Medicine, Vol. 19, No. 3, (539-548), Online publication date: 1-Mar-2023. An adaptive network model of the role of the microbiome-gut-brain axis in insomniaBanerjee S, Chitty C, Lee Q and Treur J Cognitive Systems Research, 10.1016/j.cogsys.2022.12.002, Vol. 78, , (106-121), Online publication date: 1-Mar-2023. The effect of insomnia and shift working on psychological well-being among general public hospital nursesAbdulah D and Suleman S Kontakt, 10.32725/kont.2023.005 Evaluation of Correlation between Sleep and Psychiatric Disorders in a Population of Night Shift Workers: A Pilot StudyCirrincione L, Plescia F, Malta G, Campagna M, Lecca L, Skerjanc A, Carena E, Baylon V, Theodoridou K, Fruscione S and Cannizzaro E International Journal of Environmental Research and Public Health, 10.3390/ijerph20043756, Vol. 20, No. 4, (3756) Long-Term Use of Insomnia Medications: An Appraisal of the Current Clinical and Scientific EvidenceZee P, Bertisch S, Morin C, Pelayo R, Watson N, Winkelman J and Krystal A Journal of Clinical Medicine, 10.3390/jcm12041629, Vol. 12, No. 4, (1629) The Feasibility of Using Smartphone Sensors to Track Insomnia, Depression, and Anxiety in Adults and Young Adults: Narrative ReviewAlamoudi D, Breeze E, Crawley E and Nabney I JMIR mHealth and uHealth, 10.2196/44123, Vol. 11, , (e44123) Prevalence of insomnia and its association with quality of life among Macau residents shortly after the summer 2022 COVID-19 outbreak: A network analysis perspectiveChen P, Zhang L, Sha S, Lam M, Lok K, Chow I, Si T, Su Z, Cheung T, Feng Y, Jackson T and Xiang Y Frontiers in Psychiatry, 10.3389/fpsyt.2023.1113122, Vol. 14, Effects of quetiapine on sleep: A systematic review and meta-analysis of clinical trialsLin C, Chiang C, Tseng M, Tam K and Loh E European Neuropsychopharmacology, 10.1016/j.euroneuro.2022.11.008, Vol. 67, , (22-36), Online publication date: 1-Feb-2023. Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of InsomniaHan A, Burroughs C, Falgoust E, Hasoon J, Hunt G, Kakazu J,